rs12251307 — IL2RA IL-2 receptor alpha chain variant

IL2RA rs12251307 — A Shared Immune Gateway for Eczema, Asthma, and Autoimmunity

About 19 kilobases downstream of IL2RA¹¹ IL2RA
the gene encoding CD25, the alpha chain of the high-affinity interleukin-2 receptor; CD25 is the defining surface marker of regulatory T cells (Tregs), rs12251307 sits in a region of open chromatin that functions as a long-range regulatory element for the locus. IL-2 signaling through CD25 is the central survival and activation signal for regulatory T cells²² regulatory T cells
Tregs are CD4+ immune cells that suppress excessive immune responses and maintain self-tolerance; CD25 gives Tregs preferential access to IL-2 at physiologically low concentrations. Variants across the IL2RA locus — including rs12251307 — collectively tune how much CD25 gets expressed on Treg surfaces, how sensitive those Tregs are to IL-2, and consequently how well the immune system is held in check. The T allele at this downstream position tags a configuration of the locus associated with mildly impaired immune regulation across multiple atopic and autoimmune phenotypes.

The Mechanism

rs12251307 is located on the plus strand of chromosome 10 at position 6,081,532 (GRCh38), classified as an intergenic variant with C as the GRCh38 reference allele and T as the alternate. The region around IL2RA contains multiple independent regulatory variants that together influence sIL-2RA shedding³³ sIL-2RA shedding
the alpha chain of the IL-2 receptor can be cleaved and released from the cell surface as soluble IL-2RA, which competes with membrane-bound receptors for available IL-2, thereby reducing the effective IL-2 signal reaching Tregs, intron-1 enhancer activity, and promoter accessibility. The T allele at rs12251307 acts as a tag for a broader haplotype across this ~20 kb region. Because IL2RA is on the minus strand, gene regulatory elements can extend well beyond the transcribed sequence into the 3' flank, and enhancer-promoter loops at this distance are well documented in immune loci. Mechanistically, T-allele haplotypes at this locus are associated with lower Treg STAT5 phosphorylation⁴⁴ Treg STAT5 phosphorylation
STAT5 is the intracellular signaling molecule activated when IL-2 binds to CD25-containing high-affinity receptor complexes; less pSTAT5 means weaker Treg activation even when IL-2 is present and reduced Treg suppressive capacity downstream of IL-2 stimulation.

The Evidence

The strongest signal comes from the 2023 Nature Communications atopic dermatitis GWAS meta-analysis. Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts⁵⁵ Budu-Aggrey et al. analyzed hundreds of thousands of individuals across European and multi-ancestry cohorts, identifying rs12251307-T as a genome-wide significant risk allele for atopic dermatitis (OR 1.10, 95% CI 1.09–1.11; p = 5×10⁻¹⁰⁷). The paper explicitly highlighted the IL2RA locus as evidence that atopic dermatitis involves systemic immune dysregulation — not just skin-barrier defects — placing it alongside classic HLA and cytokine loci. The T allele risk frequency in the atopic dermatitis cohort was ~12%.

Earlier evidence established this locus in type 1 diabetes: the Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009)⁶⁶ Type 1 Diabetes Genetics Consortium meta-analysis (Barrett et al. 2009) identified the same 10p15 region at genome-wide significance (p = 1×10⁻¹³), consistent with the IL2RA locus being a shared hub for autoimmune susceptibility. A 2023 cross-trait GWAS also found rs12251307 among loci shared between rheumatoid arthritis and type 1 diabetes (Wen & Yu 2023)⁷⁷ (Wen & Yu 2023). The variant also reaches genome-wide significance for asthma susceptibility (OR ~1.09, p = 2×10⁻⁹), extending the phenotypic spectrum to atopic disease more broadly. The functional biology underlying all these associations is coherent: Treg dysfunction resulting from impaired CD25 expression or IL-2 signaling permits both autoimmune attack (T1D, RA) and dysregulated type 2 immune responses (atopic dermatitis, asthma) depending on the downstream context.

Practical Actions

The T allele confers a small per-allele risk increase (OR ~1.10 per T copy). In absolute terms, the lifetime risk increase is modest but meaningful in context of a personal or family history of atopic or autoimmune conditions. Carriers cannot directly manipulate CD25 expression, but the downstream biology — Treg function and IL-2 signaling — is modulated by vitamin D status and IL-2 availability. The most clinically actionable implication for T allele carriers is awareness of early-onset warning signs across atopic and autoimmune phenotypes and timely engagement with a dermatologist or immunologist when symptoms arise.

Interactions

rs12251307 is in the same genomic locus as several other IL2RA variants already catalogued: rs2104286⁸⁸ rs2104286 (intron 1, soluble IL-2RA shedding), rs12722489⁹⁹ rs12722489 (intron 1, estrogen-responsive enhancer), rs41295061¹⁰¹⁰ rs41295061 (regulatory, T1D locus), and rs2256774¹¹¹¹ rs2256774 (intronic). These variants are in partial linkage disequilibrium; rs12251307 represents an additional, partially independent signal at the 3' end of the locus. Compound heterozygosity across multiple IL2RA locus variants may further impair Treg function, though the specific interaction effects have not been quantified for this downstream position. The locus also interacts biologically with IL-2 pathway genes including IL2RB¹²¹² IL2RB and IL2¹³¹³ IL2; variants in these genes that reduce IL-2 production or beta-chain signaling would compound the signaling deficit created by impaired CD25 expression.